Access Resources
1711 - 1720 of 7540 Results
Title
Year
-
RESTRICTEDTitle: Physician‐Assisted Dying: Access and Utilization in Patients with Movement DisordersJournal Name: Movement DisordersPublisher: WileyVol: 37Issue #: 4Start Page: 694End Page: 698Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.28964Citation Count: 2
- Validation of the Arabic Version of the Movement Disorder Society‐Unified Parkinson's Disease Rating Scale2022RESTRICTEDTitle: Validation of the Arabic Version of the Movement Disorder Society‐Unified Parkinson's Disease Rating ScaleJournal Name: Movement DisordersPublisher: WileyVol: 37Issue #: 4Start Page: 826End Page: 841Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.28905Citation Count: 2
- CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers2022RESTRICTEDTitle: CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative BiomarkersJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.834580Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.834580/pdfCitation Count: 16
-
RESTRICTEDTitle: Etiology, pathological characteristics, and clinical management of black pleural effusionJournal Name: MedicinePublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 101Issue #: 8Start Page: e28130End Page: e28130Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1097/md.0000000000028130Best OA location URL: https://doi.org/10.1097/md.0000000000028130Citation Count: 6
-
RESTRICTEDTitle: Nanobodies as allosteric modulators of Parkinson’s disease–associated LRRK2Journal Name: Proceedings of the National Academy of SciencesPublisher: Proceedings of the National Academy of SciencesVol: 119Issue #: 9Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1073/pnas.2112712119Best OA location URL: https://doi.org/10.1073/pnas.2112712119Citation Count: 15
-
RESTRICTEDTitle: Slowing Parkinson’s Disease Progression with Vaccination and Other ImmunotherapiesJournal Name: CNS DrugsPublisher: Springer Science and Business Media LLCVol: 36Issue #: 4Start Page: 327End Page: 343Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s40263-022-00903-7Citation Count: 6
-
RESTRICTEDTitle: Defining Utility Values for Chorea Health States in Patients with Huntington’s DiseaseJournal Name: Advances in TherapyPublisher: Springer Science and Business Media LLCVol: 39Issue #: 4Start Page: 1784End Page: 1793Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s12325-022-02046-zBest OA location URL: https://link.springer.com/content/pdf/10.1007/s12325-022-02046-z.pdfCitation Count: 1
- Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads2022RESTRICTEDTitle: Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beadsJournal Name: eLifePublisher: eLife Sciences Publications, LtdVol: 11Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.7554/elife.73971Best OA location URL: https://doi.org/10.7554/elife.73971Citation Count: 36
- Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study2022RESTRICTEDTitle: Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension StudyJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.773999Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.773999/pdfCitation Count: 2
- Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease2022RESTRICTEDTitle: Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s diseaseJournal Name: Molecular NeurodegenerationPublisher: Springer Science and Business Media LLCVol: 17Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1186/s13024-022-00520-4Best OA location URL: https://molecularneurodegeneration.biomedcentral.com/track/pdf/10.1186/s13024-022-00520-4Citation Count: 8